SCHEMBL4767079

SCHEMBL4767079

COc1cccc(S(=O)(=O)N(C(=O)C(CC(C)C)NC(=O)c2cc3cccc(OC)c3o2)[C@H]2CCCNCC2=O)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 4/20 0.38
TAS1R1 Q7RTX1 4/20 0.38
ALDH1A1 P00352 4/20 0.36
RAB9A P51151 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
KDM4E B2RXH2 3/20 0.36
CHRNA7 P36544 2/20 0.36
RXFP1 Q9HBX9 2/20 0.36
MMP2 P08253 1/20 0.35
MMP14 P50281 1/20 0.35
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35
NPC1 O15118 2/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
MEN1 O00255 1/20 0.34
CYP1A2 P05177 1/20 0.34
PKM P14618 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4767072 1.00 TAS1R3 (0.38) TAS1R3TAS1R1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL6590290 0.93 KDM4E (0.36) TAS1R3TAS1R1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL6590286 0.93 KDM4E (0.36) TAS1R3TAS1R1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL6586348 0.92 TAS1R3 (0.43) TAS1R3TAS1R1CTSK
SCHEMBL6586343 0.92 TAS1R3 (0.43) TAS1R3TAS1R1CTSK
SCHEMBL4763065 0.91 MMP2 (0.37) TAS1R3TAS1R1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL4761879 0.91 MMP2 (0.37) TAS1R3TAS1R1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL4762061 0.91 TAS1R3 (0.47) TAS1R3TAS1R1ALDH1A1RAB9ACTSK
SCHEMBL4762063 0.91 TAS1R3 (0.47) TAS1R3TAS1R1ALDH1A1RAB9ACTSK
SCHEMBL4770836 0.90 TAS1R3 (0.51) TAS1R3TAS1R1CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1320370-A4 METHOD OF TREATMENT SMITHKLINE BEECHAM CORP (US) 2008-10-22 EP disclosed
EP-1307204-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2004-06-02 EP disclosed
EP-1320370-A1 METHOD OF TREATMENT SmithKline Beecham Corporation (US) 2003-06-25 EP disclosed
EP-1307204-A1 PROTEASE INHIBITORS SmithKline Beecham Corporation (US) 2003-05-07 EP disclosed
EP-1158986-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2002-03-27 EP disclosed
WO-2002017924-A1 METHOD OF TREATMENT SMITHKLINE BEECHAM CORPORATION (GB) 2002-03-07 WO disclosed
WO-2001095911-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-12-20 WO disclosed
EP-1158986-A1 PROTEASE INHIBITORS SmithKline Beecham Corporation (US) 2001-12-05 EP disclosed
WO-2000038687-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2000-07-06 WO disclosed